GLP-1 secretion by microglial cells and decreased CNS expression in obesity
Open Access
- 23 December 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Neuroinflammation
- Vol. 9 (1), 276
- https://doi.org/10.1186/1742-2094-9-276
Abstract
Type 2 diabetes (T2D) is a strong risk factor for developing neurodegenerative pathologies. T2D patients have a deficiency in the intestinal incretin hormone GLP-1, which has been shown to exert neuroprotective and anti-inflammatory properties in the brain.Keywords
This publication has 33 references indexed in Scilit:
- Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic ratsClinical Science, 2012
- The CCAAT/enhancer binding protein (C/EBP) δ is differently regulated by fibrillar and oligomeric forms of the Alzheimer amyloid-β peptideJournal of Neuroinflammation, 2011
- Palmitate and insulin synergistically induce IL-6 expression in human monocytesCardiovascular Diabetology, 2010
- Increased Brain Fatty Acid Uptake in Metabolic SyndromeDiabetes, 2010
- Enhancing the GLP‐1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cellsJournal of Neurochemistry, 2010
- Minireview: Finding the Sweet Spot: Peripheral Versus Central Glucagon-Like Peptide 1 Action in Feeding and Glucose HomeostasisEndocrinology, 2009
- Incidence and Risk Factors for Stroke in Type 2 Diabetic PatientsStroke, 2007
- Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathyExperimental Neurology, 2007
- The role of gut hormones in glucose homeostasisJCI Insight, 2007
- Increases in serum unbound free fatty acid levels following coronary angioplastyThe American Journal of Cardiology, 1996